Monoclonal antibodies for the treatment of COVID-19 infection in children

References

• Omer SB, Malani PN. Booster vaccination to prevent COVID-19 in the era of omicron: an effective part of a layered public health approach. JAMA. 2022;327(7):628–629. PubMed PMID: 35061011.
   PubMed Web of Science ®Google Scholar
• Chenchula S, Karunakaran P, Sharma S, et al.Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review.J Med Virol.2022;94(7):2969–2976. Epub 20220314. PubMed PMID: 35246846; PubMed Central PMCID: PMC9088621
   PubMed Web of Science ®Google Scholar
• Murdaca G, Noberasco G, Olobardi D, et al. Current take on systemic sclerosis patients’ vaccination recommendations. Vaccines (Basel). 2021;9(12). Epub 20211202. PubMed PMID: 34960174; PubMed Central PMCID: PMC8708328. doi: 10.3390/vaccines9121426.
   Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. Epub 20210421. PubMed PMID: 33882225; PubMed Central PMCID: PMC8220996
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172–1183. Epub 20210630. PubMed PMID: 34192426; PubMed Central PMCID: PMC8262625
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. Epub 20201210. PubMed PMID: 33301246; PubMed Central PMCID: PMC7745181
   PubMed Web of Science ®Google Scholar
• Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250. Epub 20210527. PubMed PMID: 34043894; PubMed Central PMCID: PMC8174030
   PubMed Web of Science ®Google Scholar
• Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(11):422–428. Epub 20220318. PubMed PMID: 35298453; PubMed Central PMCID: PMC8942308
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. Epub 20201230. PubMed PMID: 33378609; PubMed Central PMCID: PMC7787219
   PubMed Web of Science ®Google Scholar
• Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):2241–2251. Epub 20210811. PubMed PMID: 34379915; PubMed Central PMCID: PMC8385554
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–1546. Epub 20220302. PubMed PMID: 35249272; PubMed Central PMCID: PMC8908811
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457–66.e4. Epub 20220106. PubMed PMID: 34995482; PubMed Central PMCID: PMC8733787
   PubMed Web of Science ®Google Scholar
• Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases - borrowing from history. N Engl J Med.2018;378(16):1469–1472. Epub 20180307. PubMed PMID: 29513615
   PubMed Web of Science ®Google Scholar
• Zhou D, Zhou R, Chen Z. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunother Adv. 2022;2(1):ltab027. Epub 20211230. PubMed PMID: 35915816; PubMed Central PMCID: PMC8755319
   PubMedGoogle Scholar
• Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. 2022:2022 March 10. 22272100. doi: 10.1101/2022.03.10.22272100.
   Google Scholar
• Westendorf K, Žentelis S, Wang L, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39(7):110812. Epub 20220425. PubMed PMID: 35568025; PubMed Central PMCID: PMC9035363
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. PubMed PMID: 33475701; PubMed Central PMCID: PMC7821080.
   PubMed Web of Science ®Google Scholar
• Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382–1392. Epub 20210714. PubMed PMID: 34260849; PubMed Central PMCID: PMC8314785
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–251. Epub 20201217. PubMed PMID: 33332778; PubMed Central PMCID: PMC7781102
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. Epub 20211027. PubMed PMID: 34706189
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med. 2022;386(10):995–998. Epub 20220126. PubMed PMID: 35081300; PubMed Central PMCID: PMC8809508
   PubMed Web of Science ®Google Scholar
• Tao K, Tzou PL, Kosakovsky Pond SL, et al. Susceptibility of SARS-CoV-2 omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. Microbiol Spectr. 2022;10(4):e0092622. Epub 20220614. PubMed PMID: 35700134.
   PubMedGoogle Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81. Epub 20210929. PubMed PMID: 34587383; PubMed Central PMCID: PMC8522800
   PubMed Web of Science ®Google Scholar
• Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468–470. Epub 20220720. PubMed PMID: 35857646; PubMed Central PMCID: PMC9342381 .
   PubMed Web of Science ®Google Scholar
• Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604(7906):553–556. Epub 20220303. PubMed PMID: 35240676; PubMed Central PMCID: PMC9021018
   PubMed Web of Science ®Google Scholar
• Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188–2200. Epub 20220420. PubMed PMID: 35443106; PubMed Central PMCID: PMC9069994
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. Epub 20200204. PubMed PMID: 32020029; PubMed Central PMCID: PMC7054408
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826. Epub 20201008. PubMed PMID: 32445440; PubMed Central PMCID: PMC7262788
   PubMed Web of Science ®Google Scholar
• Goldman DL, Aldrich ML, Hagmann SHF, et al. Compassionate use of remdesivir in children with severe COVID-19. Pediatrics. 2021;147(5). PubMed PMID: 33883243. DOI:10.1542/peds.2020-047803.
   Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. Epub 20220216. PubMed PMID: 35172054; PubMed Central PMCID: PMC8908851
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, da Silva Mm G, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. Epub 20211216. PubMed PMID: 34914868; PubMed Central PMCID: PMC8693688
   PubMed Web of Science ®Google Scholar
• Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252. Epub 20220124. PubMed PMID: 35085683; PubMed Central PMCID: PMC8785409.
   PubMed Web of Science ®Google Scholar
• Smith K, Garman L, Wrammert J, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372–384. PubMed PMID: 19247287; PubMed Central PMCID: PMC2750034.
   PubMed Web of Science ®Google Scholar
• Chen P, Datta G, Grace Li Y, et al. First-in-human study of bamlanivimab in a randomized trial of hospitalized patients with COVID-19. Clin Pharmacol Ther. 2021;110(6):1467–1477. Epub 20211016. PubMed PMID: 34455583; PubMed Central PMCID: PMC8653186
   PubMed Web of Science ®Google Scholar
• Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586(7827):113–119. Epub 20200724. PubMed PMID: 32707573; PubMed Central PMCID: PMC7603405
   PubMed Web of Science ®Google Scholar
• Bolken TC, Hruby DE. Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company. Antiviral Res.2008;77(1):1–5; Epub 20070815. PubMed PMID: 17765333; PubMed Central PMCID: PMC2972676;
   PubMed Web of Science ®Google Scholar
• Ward DJ, Hammond E, Linden-Phillips L, et al.Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study.BMJ Open.2015;5(11):e009333. Epub 20151116. PubMed PMID: 26576812; PubMed Central PMCID: PMC4654359
   PubMed Web of Science ®Google Scholar
• Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022;82(5):585–591. PubMed PMID: 35305258; PubMed Central PMCID: PMC8933659.
   PubMed Web of Science ®Google Scholar
• Tempestilli M, Caputi P, Avataneo V, et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother. 2020;75(10):2977–2980. PubMed PMID: 32607555; PubMed Central PMCID: PMC7337789.
   PubMed Web of Science ®Google Scholar
• Eng H, Dantonio AL, Kadar EP, et al. Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-Like Protease, across animals and humans. Drug Metab Dispos. 2022;50(5):576–590. Epub 20220213. PubMed PMID: 35153195
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Bertz RJR. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275–291. PubMed PMID: 9812178.
   PubMed Web of Science ®Google Scholar
• Mak G, Dassner AM, Hammer BM, et al. Safety and tolerability of monoclonal antibody therapies for treatment of COVID-19 in pediatric patients. Pediatr Infect Dis J. 2021;40(12):e507–e9. PubMed PMID: 34260492; PubMed Central PMCID: PMC8575082.
   PubMed Web of Science ®Google Scholar
• Romani L, Calò Carducci FI, Chiurchiù S, et al. Safety of monoclonal antibodies in children affected by SARS-CoV-2 infection. Children (Basel). 2022;9(3). Epub 20220307. PubMed PMID: 35327741; PubMed Central PMCID: PMC8947030. doi: 10.3390/children9030369.
   PubMed Web of Science ®Google Scholar
• Wolf J, Abzug MJ, Wattier RL, et al. Initial guidance on use of monoclonal antibody therapy for treatment of coronavirus disease 2019 in children and adolescents. J Pediatric Infect Dis Soc. 2021;10(5):629–634. PubMed PMID: 33388760; PubMed Central PMCID: PMC7799019.
   PubMed Web of Science ®Google Scholar
• Wolf J, Abzug MJ, Anosike BI, et al.Updated guidance on use and prioritization of monoclonal antibody therapy for treatment of COVID-19 in adolescents. J Pediatric Infect Dis Soc. 2022;11(5):177–185. PubMed PMID: 35107571; PubMed Central PMCID: PMC8903349.
   PubMed Web of Science ®Google Scholar
• Bailey LC, Razzaghi H, Burrows EK, et al. Assessment of 135 794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr. 2021;175(2):176–184.
   PubMed Web of Science ®Google Scholar
• Delavari S, Abolhassani H, Abolnezhadian F, et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. J Clin Immunol. 2021;41(2):345–355. Epub 20201201. PubMed PMID: 33263173; PubMed Central PMCID: PMC7707812
   PubMed Web of Science ®Google Scholar
• London J, Boutboul D, Lacombe K, et al. Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy. J Clin Immunol. 2021;41(2):356–361. Epub 20201120. PubMed PMID: 33219491; PubMed Central PMCID: PMC7678568
   PubMed Web of Science ®Google Scholar
• Hensley MK, Bain WG, Jacobs J, et al. Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study. Clin Infect Dis. 2021;73(3):e815–e21. PubMed PMID: 33507235; PubMed Central PMCID: PMC7929077.
   PubMed Web of Science ®Google Scholar
• Truong TT, Ryutov A, Pandey U, et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series. EBioMedicine. 2021;67:103355. Epub 20210426. PubMed PMID: 33915337; PubMed Central PMCID: PMC8072072.
   PubMed Web of Science ®Google Scholar
• Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185–e93. Epub 20210119. PubMed PMID: 33482113; PubMed Central PMCID: PMC7816949
   PubMed Web of Science ®Google Scholar
• Goss MB, Galván NTN, Ruan W, et al. The pediatric solid organ transplant experience with COVID-19: an initial multi-center, multi-organ case series. Pediatr Transplant. 2021;25(3):e13868. Epub 20201109. PubMed PMID: 32949098; PubMed Central PMCID: PMC7537006
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland CA, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374(2244). Epub 20210917. PubMed PMID: 34535466; PubMed Central PMCID: PMC8446717. doi: 10.1136/bmj.n2244.
   Google Scholar
• Murdaca G, Greco M, Tonacci A, et al. IL-33/IL-31 axis in immune-mediated and allergic diseases. Int J Mol Sci. 2019;20(23):5856. Epub 20191122. PubMed PMID: 31766607; PubMed Central PMCID: PMC6929191
   PubMed Web of Science ®Google Scholar
• Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325(11):1074–1087. PubMed PMID: 33625505; PubMed Central PMCID: PMC7905703.
   PubMed Web of Science ®Google Scholar
• Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel). 2020;7(7). Epub 20200701. PubMed PMID: 32630212; PubMed Central PMCID: PMC7401880. doi:10.3390/children7070069.
   PubMed Web of Science ®Google Scholar
• Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev. 2021;38:51–57. Epub 20200811. PubMed PMID: 32891582; PubMed Central PMCID: PMC7417920.
   PubMed Web of Science ®Google Scholar
• Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324(3):259–269. PubMed PMID: 32511692; PubMed Central PMCID: PMC7281356.
   PubMed Web of Science ®Google Scholar
• Abrams JY, Oster ME, Godfred-Cato SE, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021;5(5):323–331. Epub 20210310. PubMed PMID: 33711293; PubMed Central PMCID: PMC7943393
   PubMedGoogle Scholar
• Esposito S, Caramelli F, Principi N. What are the risk factors for admission to the pediatric intensive unit among pediatric patients with COVID-19? Ital J Pediatr.2021;47(1):103. Epub 20210503. PubMed PMID: 33941228; PubMed Central PMCID: PMC8090919
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. Epub 20210322. PubMed PMID: 33753937; PubMed Central PMCID: PMC8893149
   PubMed Web of Science ®Google Scholar
• Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep. 2022;12(1):9950. Epub 20220623. PubMed PMID: 35739136; PubMed Central PMCID: PMC9226045
   PubMed Web of Science ®Google Scholar
• White A, Liburd LC, Coronado F. Addressing racial and ethnic disparities in COVID-19 among school-aged children: are we doing enough? Prev Chronic Dis. 2021;18:E55. Epub 20210603. PubMed PMID: 34081577; PubMed Central PMCID: PMC8220967.
   PubMed Web of Science ®Google Scholar
• Gold JAW, Rossen LM, Ahmad FB, et al. Race, ethnicity, and age trends in persons who died from COVID-19 - United States, May-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(42):1517–1521. Epub 20201023. PubMed PMID: 33090984; PubMed Central PMCID: PMC7583501
   PubMed Web of Science ®Google Scholar
• Kim L, Whitaker M, O’Halloran A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 states, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1081–1088. Epub 20200814. PubMed PMID: 32790664; PubMed Central PMCID: PMC7440125
   PubMed Web of Science ®Google Scholar
• Moreira A, Chorath K, Rajasekaran K, et al.Demographic predictors of hospitalization and mortality in US children with COVID-19.Eur J Pediatr.2021;180(5):1659–1663. Epub 20210120. PubMed PMID: 33474580; PubMed Central PMCID: PMC7817069
   PubMed Web of Science ®Google Scholar
• Musshafen LA, El-Sadek L, Lirette ST, et al.In-hospital mortality disparities among American Indian and Alaska native, black, and white patients with COVID-19.JAMA Network Open.2022;5(3):e224822. Epub 20220301. PubMed PMID: 35353166; PubMed Central PMCID: PMC8968465
   PubMed Web of Science ®Google Scholar
• Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J Pediatr. 2020;226:45–54.e1. Epub 20200805. PubMed PMID: 32768466; PubMed Central PMCID: PMC7403869.
   PubMed Web of Science ®Google Scholar
• Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Network Open. 2021;4(6):e2116420. Epub 20210601. PubMed PMID: 34110391; PubMed Central PMCID: PMC8193431
   PubMed Web of Science ®Google Scholar
• Zhang L, Poorbaugh J, Dougan M, et al. Endogenous antibody responses to SARS-CoV-2 in patients with mild or moderate COVID-19 who received bamlanivimab alone or bamlanivimab and etesevimab together. Front Immunol. 2021;12:790469. Epub 20211209. PubMed PMID: 34956222; PubMed Central PMCID: PMC8697104.
   PubMed Web of Science ®Google Scholar
• Kim PS, Dimcheff DE, Siler A, et al. Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response. Clin Immunol. 2022;236:108959. Epub 20220224. PubMed PMID: 35218964; PubMed Central PMCID: PMC8866167
   PubMed Web of Science ®Google Scholar
• Lucas C, Klein J, Sundaram ME, et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat Med. 2021;27(7):1178–1186. Epub 20210505. PubMed PMID: 33953384; PubMed Central PMCID: PMC8785364
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. Epub 20210517. PubMed PMID: 34002089
   PubMed Web of Science ®Google Scholar
• Wu EL, Kumar RN, Moore WJ, et al. Disparities in COVID-19 monoclonal antibody delivery: a retrospective cohort study. J Gen Intern Med. 2022;37(10):2505–2513. Epub 20220425. PubMed PMID: 35469360; PubMed Central PMCID: PMC9037582
   PubMed Web of Science ®Google Scholar
• Zsigmond B, Breathnach AS, Mensah A, et al.Very low rates of severe COVID-19 in children hospitalised with confirmed SARS-CoV-2 infection in London, England”.J Infect.2022;85(1):90–122. Epub 20220410. PubMed PMID: 35417737.
   PubMed Web of Science ®Google Scholar
• Smith C, Odd D, Harwood R, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. 2022;28(1):185–192. Epub 20211111. PubMed PMID: 34764489
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. 2020; Epub 20201201. PubMed PMID: 33262177. doi: 10.1136/archdischild-2020-320338.
   Web of Science ®Google Scholar
• Yan G, Zhou J, Zhu H, et al. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study. Ann Transl Med. 2022;10(11):619. PubMed PMID: 35813342; PubMed Central PMCID: PMC9263777.
   PubMed Web of Science ®Google Scholar
• Dulek DE, Fuhlbrigge RC, Tribble AC, et al. Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute coronavirus disease 2019 in pediatric patients. J Pediatric Infect Dis Soc. 2020;9(6):716–737. PubMed PMID: 32808988; PubMed Central PMCID: PMC7454742.
   PubMed Web of Science ®Google Scholar
• Zaffanello M, Piacentini G, Nosetti L, et al.The use of convalescent plasma for pediatric patients with SARS-CoV-2: a systematic literature review.Transfus Apher Sci.2021;60(2):103043. Epub 20201223. PubMed PMID: 33388249; PubMed Central PMCID: PMC7834628
   PubMed Web of Science ®Google Scholar
• Morales AC, Rice AM, Ho AT, et al. Causes and Consequences of Purifying Selection on SARS-CoV-2. Genome Biol Evol. 2021;13(10). PubMed PMID: 34427640; PubMed Central PMCID: PMC8504154. DOI:10.1093/gbe/evab196.
   Web of Science ®Google Scholar
• Tulledge-Scheitel S, Bell SJ, Larsen JJ, et al. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. J Am Geriatr Soc. 2021;69(4):868–873. Epub 20210305. PubMed PMID: 33619724; PubMed Central PMCID: PMC8013486
   PubMed Web of Science ®Google Scholar
• Malani AN, LaVasseur B, Fair J, et al. Administration of monoclonal antibody for COVID-19 in patient homes. JAMA Network Open. 2021;4(10):e2129388. Epub 20211001. PubMed PMID: 34648014; PubMed Central PMCID: PMC8517740
   PubMed Web of Science ®Google Scholar
• Walker VL, Meyer A, Paauw D, et al.Health system success in delivering bamlanivimab within post-acute and long-term care facilities.J Am Med Dir Assoc.2022;23(1):141–145. Epub 20211208. PubMed PMID: 34890559; PubMed Central PMCID: PMC8651463;
   PubMed Web of Science ®Google Scholar
• Razonable RR, Aloia NCE, Anderson RJ, et al. A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the mayo clinic model. Mayo Clin Proc. 2021;96(5):141–145. Epub 20210309. PubMed PMID: 33958056; PubMed Central PMCID: PMC7942148
   Web of Science ®Google Scholar